Russia's Biocad confirms 25 million-euro investment in new pharma plant in Finland
Russia’s leading biotech firm Biocad has confirmed its plans for the building a new pharmaceutical plant in the Finnish city of Turku at the cost of 25 million euros ($29 million), according to the company.
It is planned the new plant will specialize on the production of at least seven drugs that will be intended for the treatment of cancer and autoimmune diseases: melanoma, breast cancer, stomach cancer and some others, reports The Pharma Letter’s local correspondent.
The new plant will occupy an area of more than 3.500 m2 in the city of Turku, and will be located close to one of the leading biopharmaceutical clusters and one of the best EU universities in the field of biotechnology. The company first revealed it planned building a manufacturing plantin Finland earlier this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze